-
Mashup Score: 0
E-602 represents the first glyco-immune checkpoint inhibitor and the early safety as well as translational immunology associated with the treatment in patients with advanced cancer is promising, according to Jason Luke, MD, FACP.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1
A post-hoc analysis of the EMPOWER-Lung 1 and 3 studies demonstrates long-term survival and responses for patients with locally advanced non–small cell lung cancer treated with cemiplimab.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
EMPOWER-Lung 1 and 3 demonstrated long-term survival and responses for patients with locally advanced #NSCLC treated with #cemiplimab. https://t.co/zOuQcLAY5f
-
-
Mashup Score: 0
Topline data from part A of the THIO-101 trial showed that patients treated with THIO plus cemiplimab had mild toxicities, including grade 1 fatigue and muscle pain, and 1 case of grade 3 nausea among patients with non–small cell lung cancer.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Part A of the THIO-101 trial demonstrated that patients with #NSCLC treated with THIO plus #cemiplimab had mild toxicities, including grade 1 fatigue and muscle pain, and 1 case of grade 3 nausea. #lcsm https://t.co/TpbGjIWKCF
-
-
Mashup Score: 2
EMPOWER-Lung 3 Part 2 (NCT03409614), a double-blind, placebo-controlled phase 3 study, investigated cemiplimab (anti–PD-1) plus chemotherapy versus placebo plus chemotherapy in patients with advanced NSCLC without EGFR, ALK, or ROS1 aberrations, with either squamous or non-squamous histology, irrespective of PD-L1 levels. At primary analysis, after 16.4 months of follow-up, cemiplimab plus…
Source: Journal of Thoracic OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
EMPOWER-Lung 3: Pre-specified final OS analysis w/a 2-year follow-up shows a consistent benefit of #cemiplimab+ chemotherapy vs.chemotherapy alone in pts w/advanced squamous or non-squamous #NSCLC across PD-L1 levels https://t.co/MhWh3i3Fsn @myESMO #ELCC23 https://t.co/J2g2u6WcE9
-
-
Mashup Score: 0
A study of isatuximab and cemiplimab in 3 lymphoma subtypes will not continue, for reasons unrelated to safety.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#Isatuximab + #cemiplimab had manageable safety & modest efficacy in patients with R/R classic Hodgkin #lymphoma. However, the study was terminated due to the limited efficacy and lack of synergy of the combination. https://t.co/1FPhbIYGT1
-
-
Mashup Score: 0
Highlighting data from the EMPOWER-Lung1 trial, Marina Chiara Garassino, MD, considers the role of first-line cemiplimab in managing PD-L1–high metastatic NSCLC.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Highlighting data from the EMPOWER-Lung1 trial, Marina Chiara Garassino, MD, considers the role of first-line #cemiplimab in managing PD-L1–high metastatic #NSCLC. #lcsm | @marinagarassino @UChicagoMed https://t.co/WsiIwgdusD
-
-
Mashup Score: 0
Cemiplimab with chemotherapy appears to offer value comparable to other options and may be “an important tool to use” in first-line treatment of non-small cell lung cancer (NSCLC), said Davey Daniel, MD, chief medical officer for OneOncology, lung cancer specialist.
Source: AJMCCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
#Cemiplimab with #chemotherapy appears to offer value comparable to other options and may be "an important tool to use" in first-line treatment of non-small cell #lungcancer (#NSCLC), said Dr Davey Daniel, CMO of @OneOncology. https://t.co/YKw0f43Mbb https://t.co/xK3jdBAuMn
-
-
Mashup Score: 1
Positive Study 16113 results have led the FDA to grant approval to to cemiplimab in combination with chemotherapy for the treatment of patients with advanced non–small cell lung cancer.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
ICYMI: Positive Study 16113 results have led the #FDA to grant approval to to #cemiplimab in combination with chemotherapy for the treatment of patients with advanced non–small cell lung cancer. #lcsm #nsclc https://t.co/erG4d5PuM6
-
-
Mashup Score: 1
On November 8, 2022, the Food and Drug Administration approved cemiplimab-rwlc (Libtayo, Regeneron Pharmaceuticals, Inc.) in combination with platinum-based chemotherapy for adult patients with advanced non-small cell lung cancer (NSCLC) with no EGFR, ALK, or ROS1 aberrations.
Categories: Hem/Oncs, Latest HeadlinesTweet-
🔥@FDAOncology approves 1L #cemiplimab + chemo for pts w NSCLC mOS: 21.9 vs 13 months (compared to chemo alone) based on #EMPOWER-Lung ➡️ Now we have 5 🖐IO 🫁drugs approved & I hope ‘Empowered’ to see some 💰 competition which is good for pts. #lcsm https://t.co/BiiOf1huo2
-
-
Mashup Score: 0
The FDA approved cemiplimab (Libtayo) in combination with platinum-based chemotherapy for the first-line treatment of advanced non-small cell lung cancer (NSCLC) with no EGFR, ALK or ROS1 aberrations.
Source: AJMCCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
FDA Approves #Cemiplimab Plus Chemotherapy as First-Line Non-small Cell #LungCancer (NSCLC) Treatment https://t.co/KTShSNyV6i https://t.co/B0yzai1Qxu
-
The first patient was dosed with the combination of E-602 and #cemiplimab in the phase 2 GLIMMER-01 clinical trial. #oncology https://t.co/M2Q6RGSxfC